Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Vaping: early-phase trial registry
9 of 19 indexed Vaping trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 9 currently recruiting · #902 of 28,707 conditions by registered trial count
Vaping: 19 US clinical trials tracked, 9 recruiting.
Vaping is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of California, San Francisco, running 3 of these trials.
Enrollment posture brief
Registry condition vaping
OPEN 9 | RECR 47% | LATE 0 | EARLY 2 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Stage I (47% recruiting · 19 trials)
Vaping lists 9 open slots (47% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Vaping on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Vaping recruits in line with its size-band peers.
9 of 19 indexed trials (47.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Vaping research.
University of California, San Francisco accounts for 3 of 19 trials (15.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Vaping enrolment sits around 300 participants.
Median target enrolment is 300 among the 19 trials that report a genuine target (sentinel values excluded). 7 of those (36.8%) plan for fewer than 100 participants.
-
Vaping research is mostly interventional.
16 interventional and 3 observational studies make up this index (84.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
Perceived Effectiveness of Vaping Prevention Ads Among Adolescents and Young Adults
UNC Lineberger Comprehensive Cancer Center
NCT07116837
Implementing an Adolescent and Young Adult (AYA) mHealth Vaping Cessation Program Into Oncology Clinics
St. Jude Children's Research Hospital
NCT05967585
Behavioral Intervention for Youth to Promote Vaping Cessation
Massachusetts General Hospital
NCT06765291
A Trial of Varenicline for E-cigarette Cessation
Yale University
NCT07040566
Non-invasive Vagus Nerve Stimulation (nVNS) and Cognition in Young Adult Vapers - A Pilot Study
Temple University
NCT06804109
Vape Use Among Younger & Older Smokers
Abramson Cancer Center at Penn Medicine
NCT07214168
Early Detection of Vaping-related Vascular Diseases
University of Miami
NCT05454267
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
University of California, San Francisco
NCT05999383
Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol
University of California, Los Angeles
NCT04661683
Network Intervention to Prevent Vaping
University of Rochester
NCT04678245
Perioperative Vaping Complications
Navy Medical Center San Diego
NCT05912023
Text Message Quit Vaping Intervention for Adolescents
Truth Initiative
NCT04919590
Impact of Vaping Prevention Advertisements
UNC Lineberger Comprehensive Cancer Center
NCT04836455
PACE Vape Messaging Study
University of Vermont
NCT04450537
Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents
University of California, San Francisco
NCT04707911
Vaper to Vaper: A Multimodal Mobile Peer Driven Intervention to Support Adolescents in Quitting Vaping
University of Massachusetts, Worcester
NCT05140915
Acute Effects of TCIG vs ECIG in PLWH
University of California, Los Angeles
NCT04568395
Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
Philip Morris Products S.A.
NCT05383508
Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes
University of California, San Francisco
NCT04053868
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Vaping records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Vaping trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Vaping page
19 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Vaping trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of California, San Francisco sponsors the most Vaping trials on record, review their full trial history before evaluating a specific study. See University of California, San Francisco's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vaping condition card totals 19 registered trials; most-linked intervention Tobacco; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.